Scholarlink

Purpose <p>The risk of ipsilateral breast tumor recurrence (IBTR) and the prognostic outcomes of breast-conserving surgery (BCS) for germline <i>BRCA1/2</i> pathogenic variant carriers (<i>BRCA</i>+) remain controversial. This study aimed to investigate the differences in the incidence of IBTR and prognosis between <i>BRCA</i> + and noncarriers (<i>BRCA</i>–) after BCS.</p> Methods <p>A retrospective chart review was performed in patients with stage 0–III breast cancer who underwent genetic testing for germline <i>BRCA1/2</i> and BCS between 1996 and 2020. We compared the incidence of IBTR and the characteristics and prognostic outcomes of IBTR, including overall survival (OS), breast cancer-specific survival (BCSS), and distant recurrence-free survival (DRFS), between <i>BRCA</i> + and <i>BRCA</i>– after BCS.</p> Results <p>We analyzed 551 patients (587 breasts with cancer), including 61 carriers (64 breasts with cancer). During the median follow-up period of 5.3 years, the 5-year IBTR rates were 3.6% in the <i>BRCA</i>+ group and 5.1% in the <i>BRCA</i>– group, and the 10-year IBTR rates were 9.5% and 8.8%, respectively (<i>p</i> = 0.489). The median times to IBTR were 10.2 years in <i>BRCA</i> + and 3.5 years in <i>BRCA</i>–. The discordance rate of cancer subtypes between IBTR and primary cancer was significantly higher in <i>BRCA</i>+ than in <i>BRCA</i>– (<i>p</i> = 0.012). No significant differences were observed in the OS, BCSS, or DRFS between the two cohorts.</p> Conclusion <p>No significant differences were observed in the IBTR risk or prognostic outcomes between <i>BRCA</i> + and <i>BRCA</i>− after BCS. However, the longer time to IBTR and the clinicopathological features potentially consistent with new primary cancers in <i>BRCA</i>+ suggest the importance of shared decision-making regarding BCS and long-term intensive breast surveillance after BCS in <i>BRCA</i>+.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery

  • 期刊论文

  • 发表日期：

    2026年5月14日

查看全文
  • Sakiko Kondo,
  • Kumiko Kida,
  • Misato Suzuki,
  • Yuka Kajiura,
  • Junko Takei,
  • Naoki Kanomata,
  • Michiko Yamanaka,
  • Atsushi Yoshida

摘要

Purpose

The risk of ipsilateral breast tumor recurrence (IBTR) and the prognostic outcomes of breast-conserving surgery (BCS) for germline BRCA1/2 pathogenic variant carriers (BRCA+) remain controversial. This study aimed to investigate the differences in the incidence of IBTR and prognosis between BRCA + and noncarriers (BRCA–) after BCS.

Methods

A retrospective chart review was performed in patients with stage 0–III breast cancer who underwent genetic testing for germline BRCA1/2 and BCS between 1996 and 2020. We compared the incidence of IBTR and the characteristics and prognostic outcomes of IBTR, including overall survival (OS), breast cancer-specific survival (BCSS), and distant recurrence-free survival (DRFS), between BRCA + and BRCA– after BCS.

Results

We analyzed 551 patients (587 breasts with cancer), including 61 carriers (64 breasts with cancer). During the median follow-up period of 5.3 years, the 5-year IBTR rates were 3.6% in the BRCA+ group and 5.1% in the BRCA– group, and the 10-year IBTR rates were 9.5% and 8.8%, respectively (p = 0.489). The median times to IBTR were 10.2 years in BRCA + and 3.5 years in BRCA–. The discordance rate of cancer subtypes between IBTR and primary cancer was significantly higher in BRCA+ than in BRCA– (p = 0.012). No significant differences were observed in the OS, BCSS, or DRFS between the two cohorts.

Conclusion

No significant differences were observed in the IBTR risk or prognostic outcomes between BRCA + and BRCA− after BCS. However, the longer time to IBTR and the clinicopathological features potentially consistent with new primary cancers in BRCA+ suggest the importance of shared decision-making regarding BCS and long-term intensive breast surveillance after BCS in BRCA+.